Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab
British Journal of Cancer (2011) - Comment
pubmed: 21102589  doi: 10.1038/sj.bjc.6605972  issn: 0007-0920  issn: 1532-1827 

A Gualberto, M L Hixon, D D Karp, D Li, S Green, M Dolled-Filhart, L G Paz-Ares, S Novello, J Blakely, C J Langer, M N Pollak